NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Stock Information for NervGen Pharma Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NervGen Pharma Corp

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Announces Proposed Public Offering of Securities
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.